



Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 9th November 2020

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Zoom. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda for December 2020.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- Nil

Ex-panel

- Nil

Removals

- Nil

NICE Approved drug applications

- **TA617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure**

Approved by NICE in January 2020

Outcome: Noted

- **TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer AND TA644 - Entrectinib for treating NTRK fusion-positive solid tumours**

Approved by NICE in August 2020

Outcome: noted

Pharmacoeconomic Board requests

- **Baracitinib for severe Rheumatoid Arthritis**

Approved by the Pharmacoeconomic Board on 04/10

Outcome: Noted

- **Pembrolizumab for PML (For noting: IFR Rejected)**

Rejected by NHS England - For noting

Outcome: Noted

4.2 Trust Medicines Policy

- **TMP - Section 3: Ordering and supply of medicines**

Routine review and update

- **TMP - Section 4: Storage of medicines**



- Routine review and update
- Update to Appendix 4.1
- Update to Section 4.6.2 to include FP10SS prescription sheets
- Update to Section 4.6.2 to include the need to lock printing trays if FP10SS are stored in these.

Outcome: Approved

• **TMP - Section 5: Handling and transport of medicines**

- Routine review and update
- Section 5.2.3 updated to include the transportation of CDs between hospitals out-of-hours.
- Addition of physician assistants to list of staff members authorised to collect medicines from Pharmacy

Outcome: Approved

• **TMP - Section 6: Controlled Drugs**

- Routine review and update
- Update to section 6.14 to make clear the process for dealing with illicit drugs received on ward/department
- Updated in line with Cerner EPMA

Outcome: Approved

• **TMP - Section 18: Medical Representatives**

- Routine review and update
- Update to information relating to the conflicts of interest and anti-bribery.
- Addition of declarations of Conflicts of Interest by Trust Medicines Group members and those submitting formulary applications.

• **TMP - Section 20: Unlicensed use of a licensed medicines**

- Routine review and update
- Addition of reference to MHRA Guidance (Note 14) relating to “Off-label” use of medicines.

Outcome: Approved

• **TMP - Section 24: Concentrated potassium solutions**

- Routine review and update

Outcome: Approved

• **TMP - Section 28: Controlled Drug Governance Policy**

- Routine review and update
- Addition of Metropolitan Police London Region Liaison Officer for Controlled Drugs contact details
- Update of the NHS England London Region Accountable Officer for Controlled Drugs name and contact details
- Addition of the [www.CDReporting .co.uk](http://www.CDReporting.co.uk) website for submission of quarterly CD Occurrence reports.
- Update of Appendix 28.3

Outcome: Approved

• **TMP - Section 30: Supply of over-labelled/pre-packed medicines on wards/departments**

- Routine review and update
- Updated to include the issuing of over-labelled packs/pre-packs in line with a Patient Group Direction (PGD).

Outcome: Approved

• **TMP - Section 22: Non-Medical Prescribing**

- Update to Trust NMP Leads

Outcome: Approved

4.3 Medicines Optimisation

• **Topical treatments for in-patients with dermatological conditions**

This policy aims to address the acquisition and application of topical treatments for inpatients with dermatological conditions addressing two main areas:



- Supply and stock of prescribed topical treatments and how to obtain these in a timely fashion and ensure the patient does not run out
- The process of applying topical steroids and emollients and how to use soap substitutes.

Outcome: Approved

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

3 Appraisals published in September 2020 since the last meeting

4 Appraisal published in October 2020

TA649 - Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

Formulary status / Action

Add to the formulary following receipt of a signed application form from the Oncology Team.

TA650 - Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

Formulary status / Action

Nil - Not recommended

TA651 - Naldemedine for treating opioid-induced constipation

Formulary status / Action

Add to the formulary following receipt of a signed application form from the Gastroenterology Team.

TA652 - Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Formulary status / Action

Nil - Terminated appraisal

TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

Formulary status / Action

Numbers likely to treat at CWH site: 3-5 patients per year

Numbers likely to treat at WMUH site: 0 patients per year (Condition not treated at WMUH Site)

TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Formulary status / Action

Numbers likely to treat at CWH site: 3-5 patients per year

Numbers likely to treat at WMUH site: 0 patients per year (Condition not treated at WMUH Site)

TA655 - Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy

Formulary status / Action

Numbers likely to treat at CWH site: 3-5 patients per year

Numbers likely to treat at WMUH site: 0 patients per year (Condition not treated at WMUH Site)

a) NICE Highly Specialised Technologies published since last meeting

1 Highly Specialised Technologies published

HST13 - Volanesorsen for treating familial chylomicronaemia syndrome

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned



4.5 IVIG requests

- **IVIG Issues for September 2020 - CWH Site**

There were 11 IVIG issues in September 2020, with 5 new requests:

Outcome: Noted

- **IVIG Issues for September 2020 - WMUH Site**

There were 7 IVIG issues in September 2020, with 2 new requests:

Outcome: Noted

- **IVIG Issues for October 2020 - CWH Site**

There were 13 IVIG issues in October 2020, with 7 new requests

Outcome: Noted

- **IVIG Issues for October 2020 - WMUH Site**

There were 16 IVIG issues in October 2020, with 8 new requests:

Outcome: Noted

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q2 2020/21**

Quarterly Controlled Drug Summary Report for Q2 2020/21

Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q2 2020/21**

Quarterly CD Accountable Officer Report for Q2 2020/21

Outcome: Noted

- **Medication Safety Group - Terms of Reference - October 2020**

Medication Safety Group - Terms of Reference - Updated October 2020

Outcome: Noted

- **Medication Safety Bulletin - World Thrombosis Day: Know Thrombosis**

Medication safety Bulletin relating to World Thrombosis Day: Know Thrombosis - Published October 2020

Outcome: Noted

- **MHRA Drug Safety Update - September 2020**

MHRA update for September 2020

Outcome: Noted

- **MHRA Drug Safety Update - October 2020**

MHRA update for October

Outcome: Noted

4.7 Meeting minutes for noting

- **Medication Safety Group - July 2020**

Minutes from Medication Safety Group meeting - July 2020

Outcome: Noted

- **Chemotherapy Service Group - July 2020**

Minutes from Chemotherapy Service Group meeting - July 2020

Outcome: Noted

4.8 Additional papers to go to Trust Patient Safety Group

- Nil



5. Any other business

• **NWLIF Panel meeting held 5/11/2020**

Highlights:

- Medroxyprogesterone Acetate (MPA) 104mg in 0.65ml suspension for Injection (Sayana-Press®) - Application from CWFT - Approved for addition to the NWLIF
- Oral Semaglutide - Approved for addition to the NWLIF.

Outcome: Noted

6. Date of next meeting

Date: 14th December

Time: 8am-9am

Location: Via Zoom

Closing date: 27th November 2020